Kapiotis S, Quehenberger P, Jilma B, Handler S, Pabinger-Fasching I, Mannhalter C, Speiser W
Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Austria.
Am J Clin Pathol. 1996 Nov;106(5):588-93. doi: 10.1093/ajcp/106.5.588.
Screening for a resistance against activated protein C (aPCR), which is in most cases caused by FV:Q506 mutation, is performed by functional tests measuring the effect of aPC on activated partial thromboplastin time (aPTT). Because of an insufficient discrimination between FV:Q506 mutation negative and positive individuals with the first generation of the functional test Coatest aPC Resistance (Chromogenix AB, Mölndal, Sweden), the definition of an arbitrary cut-off level was only possible using the results of DNA analysis. The use of an arbitrary cut-off level still resulted in unsatisfactory low sensitivity and specificity for the functional test. Thus, time- and cost-consuming DNA analyses had to be performed frequently to establish the diagnosis. The objective of this study was to evaluate an improved version of this assay that uses predilution of samples with factor V deficient plasma containing a heparin neutralizer. Using the data from 32 FV:Q506 mutation positive and 55 mutation negative individuals, the authors calculated a cut-off value resulting in an enhanced sensitivity (0.91 versus 1.0) and specificity (0.77 versus 1.0) compared to the old one. Imprecision was lowered from 5.36% (first generation) to 2.43%, in particular in samples with longer clotting times. In patients with prolonged aPTT, either caused by therapy with oral anticoagulants or heparin, correct results were obtained with the second generation assay, in contrast to the first generation assay. With this second generation assay the number of DNA analyses can be substantially reduced.
针对活化蛋白C抵抗(aPCR)的筛查,多数情况下由FV:Q506突变引起,通过功能试验来进行,该试验测量活化蛋白C对活化部分凝血活酶时间(aPTT)的影响。由于第一代功能试验Coatest aPC Resistance(Chromogenix AB,瑞典默恩达尔)在区分FV:Q506突变阴性和阳性个体方面存在不足,仅通过DNA分析结果才能定义任意临界值。使用任意临界值仍导致功能试验的敏感性和特异性低得不尽人意。因此,必须频繁进行耗时且昂贵的DNA分析以确立诊断。本研究的目的是评估该检测方法的改进版本,该版本使用含肝素中和剂的因子V缺乏血浆对样本进行预稀释。作者利用32例FV:Q506突变阳性个体和55例突变阴性个体的数据,计算出一个临界值,与旧版本相比,其敏感性(从0.91提高到1.0)和特异性(从0.77提高到1.0)均有所增强。不精密度从5.36%(第一代)降至2.43%,尤其是在凝血时间较长的样本中。在因口服抗凝剂或肝素治疗导致aPTT延长的患者中,与第一代检测方法不同,第二代检测方法能得出正确结果。使用第二代检测方法可大幅减少DNA分析的次数。